Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women's health. CVD and …

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor
receptor 2–overexpressing (HER2-positive) breast cancer is dose-independent cardiac …

Through the success of basic and disease-specific research, cancer survivors are one of the
largest growing subsets of individuals accessing the healthcare system. Interestingly …

Background Clinical trials demonstrated that women treated for breast cancer with
anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy …

BACKGROUND: Assessment of left ventricular systolic function is necessary during
trastuzumab-based chemotherapy because of potential cardiotoxicity. Deformation indices …

Purpose Treatment of breast cancer with trastuzumab is complicated by cardiotoxicity in up
to 34% of the patients. In most patients, trastuzumab-induced cardiotoxicity (TIC) is …

New anticancer therapies have led to a long life expectancy for many patients; however,
treatment-related comorbidities have become an issue for long-term cancer survivors …

The landscape of early breast cancer has changed dramat-ically with significant
advancements in early screening and diagnosis and curative-intent therapies. Indeed …

Certain success has been achieved in the treatment of cancer due to the development of
various effective chemotherapeutic drugs. However, an increase in their effectiveness …